Hongrui Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongrui Song has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Guan Wang
Jilin University
2 shared publicationsYing Meng
Shenyang Pharmaceutical University
2 shared publicationsAilong Shi
Shenyang Pharmaceutical University
1 shared publicationAlbert S.C. Chan
Hong Kong Baptist University, Kowloon Tong, Hong Kong
1 shared publicationBo Bi
School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China
1 shared publicationCheng-Long Deng
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
1 shared publication
Latest Publications
- 4 October 2020
- Published by Elsevier in Colloids and Surfaces A: Physicochemical and Engineering Aspects
- Vol. 609, 125662
Redox/NIR dual-responsive PEG-betulinic acid/pluronic-cypate prodrug micelles for chemophotothermal therapy
- 4 October 2020
- Published by Elsevier in Colloids and Surfaces A: Physicochemical and Engineering Aspects
- Vol. 609, 125662
Redox/NIR dual-responsive PEG-betulinic acid/pluronic-cypate prodrug micelles for chemophotothermal therapy
- 1 February 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 146, 460-470
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα
- 1 February 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 146, 460-470
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα
- 19 April 2015
- Published by Springer Nature in Chemical Research in Chinese Universities
- Vol. 31 (3) , 388-393
Design, synthesis and biological evaluation of sulfenimine cephalosporin analogues as β-lactamase inhibitors
- 19 April 2015
- Published by Springer Nature in Chemical Research in Chinese Universities
- Vol. 31 (3) , 388-393
Design, synthesis and biological evaluation of sulfenimine cephalosporin analogues as β-lactamase inhibitors
- 25 July 2014
- Published by Springer Nature in Chemical Research in Chinese Universities
- Vol. 30 (4) , 624-631
Design, synthesis and antitumor activity of pyrrolopyrazinone-chalcone hybrids
- 25 July 2014
- Published by Springer Nature in Chemical Research in Chinese Universities
- Vol. 30 (4) , 624-631
Design, synthesis and antitumor activity of pyrrolopyrazinone-chalcone hybrids
- 23 April 2014
- Published by Elsevier in Tetrahedron Letters
- Vol. 55 (22) , 3344-3347
Organocatalytic domino reactions: synthesis of densely functionalized cyclohexene derivatives
- 23 April 2014
- Published by Elsevier in Tetrahedron Letters
- Vol. 55 (22) , 3344-3347
Organocatalytic domino reactions: synthesis of densely functionalized cyclohexene derivatives
- 1 January 2014
- Vol. 49 (1) , 61-7
[A novel dipeptidyl peptidase IV inhibitors developed through scaffold hopping and drug splicing strategy].
Though all the marketed drugs of dipeptidyl peptidase IV inhibitors are structurally different, their inherent correlation is worthy of further investigation. Herein we rapidly discovered a novel DPP-IV inhibitor 8g (IC50 = 4.9 nmol.L-1) which exhibits as good activity and selectivity as the market drugs through scaffold hopping and drug splicing strategies based on alogliptin and linagliptin. This study demonstrated that the employment of classic medicinal chemistry strategy to the marketed drugs with specific target is an efficient approach to discover novel bioactive molecules.
- 1 January 2014
- Vol. 49 (1) , 61-7
[A novel dipeptidyl peptidase IV inhibitors developed through scaffold hopping and drug splicing strategy].
Though all the marketed drugs of dipeptidyl peptidase IV inhibitors are structurally different, their inherent correlation is worthy of further investigation. Herein we rapidly discovered a novel DPP-IV inhibitor 8g (IC50 = 4.9 nmol.L-1) which exhibits as good activity and selectivity as the market drugs through scaffold hopping and drug splicing strategies based on alogliptin and linagliptin. This study demonstrated that the employment of classic medicinal chemistry strategy to the marketed drugs with specific target is an efficient approach to discover novel bioactive molecules.
- 20 May 2013
- Published by Elsevier in Chinese Chemical Letters
- Vol. 24 (7) , 619-621
Synthesis and biological evaluation of new pyrrolopyrazinone compounds as potential antitumor agents
- 20 May 2013
- Published by Elsevier in Chinese Chemical Letters
- Vol. 24 (7) , 619-621
Synthesis and biological evaluation of new pyrrolopyrazinone compounds as potential antitumor agents
- Open Access
Design, Synthesis and Biological Evaluation of N-Sulfonyl Homoserine Lactone Derivatives as Inhibitors of Quorum Sensing in Chromobacterium violaceum
A novel series of N-sulfonyl homoserine lactone derivatives 5a–l has been designed, synthesized and evaluated for quorum sensing inhibitory activities towards violacein production. Of the compounds synthesized, compound 5h was found to possess an excellent level of enantiopurity (99.2% e.e.). The results indicated that compounds bearing an ortho substituent on their phenyl ring exhibited excellent levels of inhibitory activity against violacein production. Compounds 5h and 5k in particular, with IC50 values of 1.64 and 1.66 µM, respectively, were identified as promising lead compounds for further structural modification.
Open AccessDesign, Synthesis and Biological Evaluation of N-Sulfonyl Homoserine Lactone Derivatives as Inhibitors of Quorum Sensing in Chromobacterium violaceum
A novel series of N-sulfonyl homoserine lactone derivatives 5a–l has been designed, synthesized and evaluated for quorum sensing inhibitory activities towards violacein production. Of the compounds synthesized, compound 5h was found to possess an excellent level of enantiopurity (99.2% e.e.). The results indicated that compounds bearing an ortho substituent on their phenyl ring exhibited excellent levels of inhibitory activity against violacein production. Compounds 5h and 5k in particular, with IC50 values of 1.64 and 1.66 µM, respectively, were identified as promising lead compounds for further structural modification.
- Open Access
Synthesis and Cytotoxic Activity of Some Novel N-Pyridinyl-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide Derivatives
A series of novel compounds bearing imidazo[2,1-b]thiazole scaffolds were designed and synthesized based on the optimization of the virtual screening hit compound N-(6-morpholinopyridin-3-yl)-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide (5a), and tested for their cytotoxicity against human cancer cell lines, including HepG2 and MDA-MB-231. The results indicated that the compound 2-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)-N-(6-(4-(4-methoxybenzyl)piperazin-1-yl)pyridin-3-yl)acetamide (5l), with slightly higher inhibition on VEGFR2 than 5a (5.72% and 3.76% inhibitory rate at 20 μM, respectively), was a potential inhibitor against MDA-MB-231 (IC50 = 1.4 μM) compared with sorafenib (IC50 = 5.2 μM), and showed more selectivity against MDA-MB-231 than HepG2 cell line (IC50 = 22.6 μM).
Open AccessSynthesis and Cytotoxic Activity of Some Novel N-Pyridinyl-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide Derivatives
A series of novel compounds bearing imidazo[2,1-b]thiazole scaffolds were designed and synthesized based on the optimization of the virtual screening hit compound N-(6-morpholinopyridin-3-yl)-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide (5a), and tested for their cytotoxicity against human cancer cell lines, including HepG2 and MDA-MB-231. The results indicated that the compound 2-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)-N-(6-(4-(4-methoxybenzyl)piperazin-1-yl)pyridin-3-yl)acetamide (5l), with slightly higher inhibition on VEGFR2 than 5a (5.72% and 3.76% inhibitory rate at 20 μM, respectively), was a potential inhibitor against MDA-MB-231 (IC50 = 1.4 μM) compared with sorafenib (IC50 = 5.2 μM), and showed more selectivity against MDA-MB-231 than HepG2 cell line (IC50 = 22.6 μM).
- Open Access
3D-QSAR Study of Combretastatin A-4 Analogs Based on Molecular Docking
Combretastatin A-4 (CA-4), its analogues and their excellent antitumoral and antivascular activities, have attracted considerable interest of medicinal chemists. In this article, a docking simulation was used to identify molecules having the same binding mode as the lead compound, and 3D-QSAR models had been built by using CoMFA based on docking. As a result, these studies indicated that the QSAR models were statistically significant with high predictabilities (CoMFA model, q2 = 0.786, r2 = 0.988). Our models may offer help to better comprehend the structure-activity relationships for this class of compounds and also facilitate the design of novel inhibitors with good chemical diversity.
Open Access3D-QSAR Study of Combretastatin A-4 Analogs Based on Molecular Docking
Combretastatin A-4 (CA-4), its analogues and their excellent antitumoral and antivascular activities, have attracted considerable interest of medicinal chemists. In this article, a docking simulation was used to identify molecules having the same binding mode as the lead compound, and 3D-QSAR models had been built by using CoMFA based on docking. As a result, these studies indicated that the QSAR models were statistically significant with high predictabilities (CoMFA model, q2 = 0.786, r2 = 0.988). Our models may offer help to better comprehend the structure-activity relationships for this class of compounds and also facilitate the design of novel inhibitors with good chemical diversity.